Aethlon Medical Identifies Long COVID Biomarker, Strengthens Hemopurifier's Therapeutic Potential — Aethlon Medical, Inc.

Event summary

Aethlon Medical published peer-reviewed research demonstrating that Long COVID patients exhibit significantly increased levels of mannosylated extracellular vesicles (EVs) that can be captured using the Hemopurifier's GNA affinity resin.
The study, conducted with UCSF investigators, found that patients with Long COVID had approximately two-fold higher levels of mannose-positive EVs compared to fully recovered individuals.
GNA affinity resin treatment significantly reduced seven circulating microRNAs associated with immune regulation and inflammatory signaling.
The research analyzed plasma samples from participants in UCSF's LIINC study and was published in the International Journal of Molecular Sciences on June 26, 2026.

The big picture

Aethlon Medical's research provides new scientific rationale for evaluating the Hemopurifier as a potential treatment for Long COVID, a condition with significant unmet medical need. The findings strengthen the device's position as a versatile platform technology with applications across multiple disease areas, including cancer and infectious diseases. This strategic development comes as Aethlon continues to advance its oncology clinical trial in Australia, highlighting the company's dual focus on immediate therapeutic priorities and long-term platform expansion.

What we're watching

Therapeutic Expansion: Whether Aethlon can leverage these findings to expand the Hemopurifier's applications beyond oncology and infectious diseases into Long COVID treatment.
Clinical Validation: The pace at which preclinical and clinical studies will be initiated to determine if removing disease-associated EVs benefits Long COVID patients.
Platform Potential: How the Hemopurifier's lectin-based capture technology may be further validated across multiple disease areas, reinforcing its platform potential.